Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Trial Type:  Treatment
Drug:  sunitinib malate
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 72 for your search:
Start Over
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SG 327/10, NCT01402089
Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000681319, FFCD-PRODIGE-16, FFCD-0905, EUDRACT-2009-017064-16, EU-21050, FFCD 0905-PRODIGE 16, NCT01164202
SU011248 versus Interferon-alfa as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181034, UCLA-0406015-01, PFIZER-A6181034, NCT00083889
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181109, 2006-004024-37, S-TRAC, NCT00375674
Clinical Trial to Assess the Importance of Nephrectomy
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: P070144, NCT00930033
Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-30073, EU-21022, PFIZER-EORTC-30073, NCT01099423
Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CSTI571BDE78T, NCT01462994
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AGS-003-007, 2012-000871-17, NCT01582672
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AB11002, NCT01694277
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-214, 2014-001750-42, NCT02231749
A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: WO29637, 2014-004684-20, NCT02420821
Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GCO 06-0906, NCT00463060
Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: ASSG01, NCT00753727
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDX1127-04, NCT02386111
Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000569863, FRE-FNCLCC-GEP-03-0603, EU-20761, EUDRACT-2006-003339-62, PFIZER-FRE-FNCLCC-GEP-03-0603, FNCLCC-GEP 03/0603, NCT00541008
Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: Sutent V5 / November 9, 2009, NCT00794950
Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MK URO 4, EUDRACT 2007-003705-27, NCT00795171
Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SNIPP, NCT00843037
Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 to 59
Sponsor: Other
Protocol IDs: CRC-01-08-03, NCT01019798
Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Sutent-IIR, NCT01069770
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000681614, ECOG-E1808, E1808, NCT01164228
Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BR01/09/10, NCT01176799
Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Yang-001, NCT01210053
Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: AN 20/04, 2008-007609-36, NCT01216371
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110096, 11-C-0096, NCT01306045
Start Over